Citations

Mayo Clinic

Showing 10 of 108599 citations.

The Use and Abuse of Thyroid Hormone
Bernet, Victor , Cappola, Anne Rentoumis

Clinical Thyroidology® | September 13, 2023 | Volume: 35 | Issue: 9 | Pages: 347-349

10.1089/ct.2023;35.347-349 Get It

A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Abuzakhm, Sonia, Sukrithan, Vineeth , Fruth, Briant, Qin, Rui , Strosberg, Jonathan , Hobday, Timothy J. , Reidy‐Lagunes, Diane , Kindler, Hedy L. , Kim, George P., Knox, Jennifer J. , Kaubisch, Andreas , Villalona‐Calero, Miguel A. , Erlichman, Charles , Shah, Manisha H. , Strosberg, Jonathan R , Knox, Jennifer J , Sukrithan, Vineeth , Semrad, Thomas John , Chen, Helen

Endocrine-Related Cancer | September 13, 2023 | Volume: 30 | Issue: 11 | Pages: No page available

10.1530/erc-22-0301 | PMID 37702588 Get It

We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, open-label, phase II study (NCT01010126) enrolled patients with advanced, recurrent, or metastatic extra-pancreatic neuroendocrine tumors. All patients were treated with temsirolimus and bevacizumab until disease progression or unacceptable toxicity. Temsirolimus 25 mg was administered i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle. Discontinuation of temsirolimus or bevacizumab did not require discontinuation of the other agent. The primary endpoints were objective response rate and 6-month progression-free survival rate. Fifty-nine patients were enrolled in this study, and 54 were evaluated for efficacy and adverse events. While median progression-free survival was 7.1 months, the median duration of treatment with temsirolimus was 3.9 months and that with bevacizumab was 3.5 months. The objective response rate of combination therapy was 2%, and 6-month progression-free survival was 48%. The most frequently reported grade 3–4 adverse events included fatigue (13%), hypertension (13%), and bleeding (13%). Close to 54% of the patients discontinued treatment due to adverse events, refusal of further treatment, or treatment delays. Three deaths occurred in the study, of which two were due to treatment-related bowel perforations. Given the minimal efficacy and increased toxicity seen with the combination of bevacizumab and temsirolimus, we do not recommend the use of this regimen in patients with advanced extra-pancreatic neuroendocrine tumors.
Association of Socioeconomic Status With Life's Essential 8 Varies by Race and Ethnicity
Williams, Amaris , Nolan, Timiya S. , Garner, Jennifer , Brewer, LaPrincess C. , Sánchez, Eduardo , Joseph, Joshua J. , Brock, Guy , Garner, Jennifer , Brewer, LaPrincess C , Sanchez, Eduardo J , Joseph, Joshua J , Nolan, Timiya S , Brock, Guy

Journal of the American Heart Association | September 13, 2023 | Volume: 12 | Issue: 18 | Pages: No page available

10.1161/jaha.122.029254 | PMID 37702137 Get It

Background The American Heart Association's Life's Essential 8 (LE8) are 8 risk factors for cardiovascular disease, with poor attainment across all racial, ethnic, and socioeconomic groups. Attainment is lowest among Americans of low socioeconomic status (SES). Evidence suggests the association of SES with LE8 may vary by race and ethnicity. Methods and Results The association of 4 SES categories (education, income‐to‐poverty line ratio, employment, insurance) with LE8 was computed in age‐adjusted linear regression models, with an interaction term for race and ethnicity, using National Health and Nutrition Examination Survey data, years 2011 to 2018. The sample (n=13 529) had a median age of 48 years (51% female) with weighting to be representative of the US population. The magnitude of positive association of college education (relative to ≤high school) with LE8 was greater among non‐Hispanic White Americans (NHWA) compared with non‐Hispanic Black Americans, Hispanic Americans, and non‐Hispanic Asian Americans (all interactions P <0.001). NHWA had a greater magnitude of positive association of income‐to‐poverty line ratio with LE8, compared with non‐Hispanic Black Americans, Hispanic Americans, and non‐Hispanic Asian Americans (all interactions P <0.001). NHWA with Medicaid compared with private insurance had a greater magnitude of negative association with LE8 compared with non‐Hispanic Black Americans, non‐Hispanic Asian Americans, or Hispanic Americans (all interactions P <0.01). NHWA unemployed due to disability or health condition (compared with employed) had a greater magnitude of negative association with LE8 than non‐Hispanic Black Americans, non‐Hispanic Asian Americans, or Hispanic Americans (all interactions P <0.05). Conclusions The magnitude of association of SES with LE8 is greatest among NHWA. More research is needed on SES's role in LE8 attainment in minority group populations.
Adeno‐associated virus‐9 reverses delayed gastric emptying of solids in diabetic mice
Li, Xiaojie , Ji, Sihan , Cipriani, Gianluca , Hillestad, Matthew L. , Eisenman, Seth T., Barry, Michael A. , Nath, Karl A. , Linden, David R. , Wright, Alec M., AlAsfoor, Shefaa , Grover, Madhusudan , Sha, Lei , Hsi, Linda C., Farrugia, Gianrico , Wright, Alec, Linden, D R , Barry, Michael A

Neurogastroenterology & Motility | September 13, 2023 | Volume: 35 | Issue: 11 | Pages: No page available

10.1111/nmo.14669 | PMID 37702100 Get It

AbstractBackgroundGastroparesis is defined by delayed gastric emptying (GE) without obstruction. Studies suggest targeting heme oxygenase‐1 (HO1) may ameliorate diabetic gastroparesis. Upregulation of HO1 expression via interleukin‐10 (IL‐10) in the gastric muscularis propria is associated with reversal of delayed GE in diabetic NOD mice. IL‐10 activates the M2 cytoprotective phenotype of macrophages and induces expression of HO1 protein. Here, we assess delivery of HO1 by recombinant adeno‐associated viruses (AAVs) in diabetic mice with delayed GE.MethodsC57BL6 diabetic delayed GE mice were injected with 1 × 1012 vg scAAV9‐cre, scAAV9‐GFP, or scAAV9‐HO1 particles. Changes to GE were assessed weekly utilizing our [13C]‐octanoic acid breath test. Stomach tissue was collected to assess the effect of scAAV9 treatment on Kit, NOS1, and HO1 expression.Key ResultsDelayed GE returned to normal within 2 weeks of treatment in 7/12 mice receiving scAAV9‐cre and in 4/5 mice that received the scAAV9‐GFP, whereas mice that received scAAV9‐HO1 did not respond in the same manner and had GE that took significantly longer to return to normal (6/7 mice at 4–6 weeks). Kit, NOS1, and HO1 protein expression in scAAV9‐GFP‐treated mice with normal GE were not significantly different compared with diabetic mice with delayed GE.Conclusions and InferencesInjection of scAAV9 into diabetic C57BL6 mice produced a biological response that resulted in acceleration of GE independently of the cargo delivered by the AAV9 vector. Further research is needed to determine whether use of AAV mediated gene transduction in the gastric muscularis propria is beneficial and warranted.
Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative
Teske, Arco J. , Moudgil, Rohit , López‐Fernández, Teresa , Barac, Ana , Brown, Sherry, Deswal, Anita , Neilan, Tomas G. , Ganatra, Sarju , Qadir, Husam Abdel, Menon, Venu , Sverdlov, Aaron L. , Cheng, Richard K. , Makhoul, Silvia , Ghosh, Arjun K. , Szmit, Sebastian , Addison, Daniel , Zhang, Lili , Herrmann, Joerg , Chong, Jun Hua , Agarwala, Vivek , Iakobishvili, Zaza , Guerrero, Patricia A., Leja, Monika, Guha, Avirup , Okwuosa, Tochukwu, Silva, Carolina Carvalho, DeCara, Jeanne M. , Bauer, Brenton , Lenneman, Carrie , Sadler, Diego , Zaha, Vlad G , Addison, Daniel , Agarwala, Vivek , Iakobishvili, Zaza , Yang, Eric , Akhter, Nausheen , Guha, Avirup , Okwuosa, Tochukwu M , Collier, Patrick , DeCara, Jeanne , Bauer, Brenton , Sadler, Diego , Deswal, Anita M , Barac, Ana , López-Fernández, Teresa , Sverdlov, Aaron L , Cheng, Richard , Brown, Sherry‐Ann , Collier, Patrick

Circulation: Cardiovascular Quality and Outcomes | September 13, 2023 | Volume: 16 | Issue: 10 | Pages: No page available

10.1161/circoutcomes.123.009905 | PMID 37702048 Get It

BACKGROUND: Global collaboration in cardio-oncology is needed to understand the prevalence of cancer therapy-related cardiovascular toxicity in different risk groups, practice settings, and geographic locations. There are limited data on the socioeconomic and racial/ethnic disparities that may impact access to care and outcomes. To address these gaps, we established the Global Cardio-Oncology Registry, a multinational, multicenter prospective registry. METHODS: We assembled cardiologists and oncologists from academic and community settings to collaborate in the first Global Cardio-Oncology Registry. Subsequently, a survey for site resources, demographics, and intention to participate was conducted. We designed an online data platform to facilitate this global initiative. RESULTS: A total of 119 sites responded to an online questionnaire on their practices and main goals of the registry: 49 US sites from 23 states and 70 international sites from 5 continents indicated a willingness to participate in the Global Cardio-Oncology Registry. Sites were more commonly led by cardiologists (85/119; 72%) and were more often university/teaching (81/119; 68%) than community based (38/119; 32%). The average number of cardio-oncology patients treated per month was 80 per site. The top 3 Global Cardio-Oncology Registry priorities in cardio-oncology care were breast cancer, hematologic malignancies, and patients treated with immune checkpoint inhibitors. Executive and scientific committees and specific committees were established. A pilot phase for breast cancer using Research Electronic Data Capture Cloud platform recently started patient enrollment. CONCLUSIONS: We present the structure for a global collaboration. Information derived from the Global Cardio-Oncology Registry will help understand the risk factors impacting cancer therapy-related cardiovascular toxicity in different geographic locations and therefore contribute to reduce access gaps in cardio-oncology care. Risk calculators will be prospectively derived and validated.
Comment on: 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults
Burnett, Allison E., Allen, Arthur L. , Ansell, Jack , Blumenstein, Marilyn, Connors, Jean M. , Dager, William E. , Kaatz, Scott , Nemeth, Ronni, O’Connor, Carlee, Ragheb, Bishoy , Rajasekhar, Anita, Sardo, Laurie A, Beek, Andrea Van, Directors, The Anticoagulation Forum Board of, Allen, Arthur L , O'Connor, Carlee, Burnett, Allison , Barnes, Geoffrey D. , May, Jori E. , Siegal, Deborah , Directors, The Anticoagulation Forum Board of

Journal of the American Geriatrics Society | September 13, 2023 | Volume: 71 | Issue: 12 | Pages: 3951-3953

10.1111/jgs.18579 | PMID 37702478 Get It

See the Reply by Semla and Steinman in this issue.
Physical Resilience as a Predictor of Lifespan and Late-Life Health in Genetically Heterogeneous Mice
Brown, Ashley K. , Mazula, Daniel L., Roberts, Lori, Roos, Carolyn M, Pearsall, Vesselina, Schafer, Marissa , White, Thomas A. , Huang, Runqing, Kumar, Navasuja , Miller, Richard A. , Roos, Carolyn, Pearsall, Vesselina M, Miller, Jordan D. , Schafer, Marissa J , Zhang, Bin , LeBrasseur, Nathan K.

The Journals of Gerontology: Series A | September 13, 2023 | Volume: 79 | Issue: 1 | Pages: No page available

10.1093/gerona/glad207 | PMID 37701988 Get It

Abstract Dynamic measures of resilience—the ability to resist and recover from a challenge—may be informative of the rate of aging before overt manifestations such as chronic disease, disability, and frailty. From this perspective mid-life resilience may predict longevity and late-life health. To test this hypothesis, we developed simple, reproducible, clinically relevant challenges, and outcome measures of physical resilience that revealed differences between and within age groups of genetically heterogeneous mice, and then examined associations between mid-life resilience and both lifespan and late-life measures of physiological function. We demonstrate that time to recovery from isoflurane anesthesia and weight change following a regimen of chemotherapy significantly differed among young, middle-aged, and older mice, and were more variable in older mice. Females that recovered faster than the median time from anesthesia (more resilient) at 12 months of age lived 8% longer than their counterparts, while more resilient males in mid-life exhibited better cardiac (fractional shortening and left ventricular volumes) and metabolic (glucose tolerance) function at 24 months of age. Moreover, female mice with less than the median weight loss at Day 3 of the cisplatin challenge lived 8% longer than those that lost more weight. In contrast, females who had more weight loss between Days 15 and 20 were relatively protected against early death. These data suggest that measures of physical resilience in mid-life may provide information about individual differences in aging, lifespan, and key parameters of late-life health.
Effectiveness of Radiofrequency Device Treatment for Nasal Valve Collapse in Patients With Nasal Obstruction
Kang, Yun Jin , Hwang, Se Hwan , Kim, Do Hyun , Hwang, Se Hwan , Kim, Do Hyun , Stybayeva, Gulnaz

Otolaryngology–Head and Neck Surgery | September 13, 2023 | Volume: 170 | Issue: 1 | Pages: 34-44

10.1002/ohn.522 | PMID 37702187 Get It

AbstractObjectiveInternal nasal valve dysfunction is a prevalent cause of nasal obstruction. This systematic review, along with a Meta‐analysis, evaluated the efficacy of temperature‐controlled radiofrequency device (RFD) treatment in alleviating nasal obstruction by rectifying nasal valve collapse.Data SourcesA comprehensive review of studies retrieved from PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases (up to December 2022) was conducted.Review MethodsWe included studies that evaluated the quality of life and nasal obstruction scores before and after RFD treatment. In addition, sham‐controlled studies were analyzed.ResultsIn total, 451 patients across 8 studies were included in the analysis. Patients who underwent RFD treatment reported a significantly enhanced quality of life 24 months after treatment compared to pretreatment scores. The rates of clinically improved states and positive responses regarding quality of life after treatment were 82% and 91%, respectively. Moreover, the disease‐specific quality of life, as assessed by the Nasal Obstruction Symptom Evaluation score, significantly improved.ConclusionRFD may help improve nasal obstruction symptoms. Further randomized clinical studies on larger cohorts are essential to substantiate its efficacy in enhancing nasal valve function.
Role of the tumour microenvironment in bladder cancer pathogenesis and value of the reverse translational approach: a tale of two species
Ahmed, Basant H. , Cheville, John C. , Rancilio, Nicholas J. , Abel, Alex , Wierson, Wesley A. , McGill, Jodi L. , Mochel, Jonathan P. , Mochel, Jonathan P , Zdyrski, Christopher , Allenspach, Karin

Clinical and Translational Discovery | September 13, 2023 | Volume: 3 | Issue: 5 | Pages: No page available

10.1002/ctd2.235 Get It

AbstractBackgroundBladder cancer is a significant malignancy in humans and canines, with high death rates and devastating clinical symptoms. Despite significant advances in therapeutic management over the years, only a small fraction of bladder cancer patients respond to immunotherapies as a second line of treatment. Since immunotherapies act on various cellular and molecular targets in the bladder cancer tumour microenvironment (TME), a greater understanding of the various types of immune cells, immune checkpoint molecules and cytokines involved in antitumour immunity will help to improve the success rate of current and novel immunotherapies, therefore enhancing the patients quality of life. Accumulating evidence shows fundamental similarities between human and canine muscle‐invasive bladder cancer (MIBC) in their clinical, histological and molecular features.AimThis review focuses on comparative aspects of MIBC in both species, highlighting the role that canines can play as a model for studying MIBC. Additionally, we discuss the various types of immune cells within bladder cancer TME that can influence the prognosis and response to immunotherapy and chemotherapy in both species.ConclusionIt remains challenging to recapitulate the heterogeneity and complexity of the bladder cancer tumour microenvironment using in vivo and in vitro models, such as zebrafish and 3D organoids models. Optimization of these techniques to create a more representative translational model has been facilitated through in vitro immune‐oncology cocultures, which are considered promising tools to help select the ideal individualized treatment options and predict disease prognosis.
EP24.02: Development of a low‐cost fetal pig simulator for ultrasound training in multiple gestations
Codsi, Elisabeth , Nitsche, Joshua F. , Decker, Marie-Luise, Brost, Brian

Ultrasound in Obstetrics & Gynecology | September 12, 2023 | Volume: 48 | Issue: S1 | Pages: 369-369

10.1002/uog.17125 Get It